| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Rayman, Margaret P. Searle, Elizabeth Kelly, Lynne Johnsen, Sigurd Bodman-Smith, Katherine Bath, Sarah C. Mao, Jinyuan Redman, Christopher W. G. |
| Description |
Country affiliation: United kingdom Author Affiliation: Rayman MP ( Department of Nutritional Sciences,School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey,GuildfordGU2 7XH,UK.); Searle E ( Nuffield Department of Obstetrics and Gynaecology, University of Oxford,OxfordOX3 9DU,UK.); Kelly L ( Anu Research Centre, Department of Obstetrics and Gynaecology, Cork University Maternity Hospital,Wilton, Cork,Republic of Ireland.); Johnsen S ( Surrey Clinical Research Centre (CRC), Faculty of Health and Medical Sciences, University of Surrey,GuildfordGU2 7XP,UK.); Bodman-Smith K ( Department of Nutritional Sciences,School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey,GuildfordGU2 7XH,UK.); Bath SC ( Department of Nutritional Sciences,School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey,GuildfordGU2 7XH,UK.); Mao J ( Department of Nutritional Sciences,School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey,GuildfordGU2 7XH,UK.); Redman CW ( Nuffield Department of Obstetrics and Gynaecology, University of Oxford,OxfordOX3 9DU,UK.) |
| Abstract |
Pre-eclampsia is a serious hypertensive condition of pregnancy associated with high maternal and fetal morbidity and mortality. Se intake or status has been linked to the occurrence of pre-eclampsia by our own work and that of others. We hypothesised that a small increase in the Se intake of UK pregnant women of inadequate Se status would protect against the risk of pre-eclampsia, as assessed by biomarkers of pre-eclampsia. In a double-blind, placebo-controlled, pilot trial, we randomised 230 primiparous pregnant women to Se (60 µg/d, as Se-enriched yeast) or placebo treatment from 12 to 14 weeks of gestation until delivery. Whole-blood Se concentration was measured at baseline and 35 weeks, and plasma selenoprotein P (SEPP1) concentration at 35 weeks. The primary outcome measure of the present study was serum soluble vascular endothelial growth factor receptor-1 (sFlt-1), an anti-angiogenic factor linked with the risk of pre-eclampsia. Other serum/plasma components related to the risk of pre-eclampsia were also measured. Between 12 and 35 weeks, whole-blood Se concentration increased significantly in the Se-treated group but decreased significantly in the placebo group. At 35 weeks, significantly higher concentrations of whole-blood Se and plasma SEPP1 were observed in the Se-treated group than in the placebo group. In line with our hypothesis, the concentration of sFlt-1 was significantly lower at 35 weeks in the Se-treated group than in the placebo group in participants in the lowest quartile of Se status at baseline (P= 0·039). None of the secondary outcome measures was significantly affected by treatment. The present finding that Se supplementation has the potential to reduce the risk of pre-eclampsia in pregnant women of low Se status needs to be validated in an adequately powered trial. |
| File Format |
HTM / HTML |
| ISSN |
00071145 |
| e-ISSN |
14752662 |
| DOI |
10.1017/S0007114514000531 |
| Journal |
British Journal of Nutrition |
| Issue Number |
1 |
| Volume Number |
112 |
| Language |
English |
| Publisher |
Cambridge University Press (on behalf of The Nutrition Society) |
| Publisher Date |
2014-07-14 |
| Publisher Place |
Great Britain (UK) |
| Access Restriction |
Open |
| Subject Keyword |
Discipline Nutritional Discipline Sciences Dietary Supplements Pre-eclampsia Prevention & Control Selenium Therapeutic Use Selenoprotein P Blood Vascular Endothelial Growth Factor Receptor-1 Yeast, Dried Biological Markers Double-blind Method Chemistry Nutritional Status Pilot Projects Epidemiology Etiology Pregnancy Pregnancy Trimester, First Deficiency Randomized Controlled Trial Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Nutrition and Dietetics Medicine |
